Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment

The Japan Morning Surge-Target Organ Protection (J-TOP) study

Motohiro Shimizu, Joji Ishikawa, Yuichiro Yano, Satoshi Hoshide, Kazuo Eguchi, Shizukiyo Ishikawa, Kazuyuki Shimada, Kazuomi Kario

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Asleep blood pressure (BP) has been shown to better reflect cardiovascular risk than awake BP in hypertensive patients. This study investigated the correlation of brain natriuretic peptide (BNP) to asleep BP during antihypertensive treatment. Methods: In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which was an open-label multicenter trial to compare bedtime or awakening dosing of candesartan (+ diuretics as needed) among individuals with home SBP higher than 135 mmHg, we evaluated 254 hypertensive patients who underwent ambulatory BP monitoring, and measured their BNP at baseline and after 6th month of treatment. Results: At follow-up, the decrease in log-transformed BNP was significantly related to the decrease in asleep SBP (r = 0.27, P < 0.001); the relationship remained significant (β = 0.20, P = 0.002) even after adjusting for the decrease in the awake SBP (β = 0.001, P = 0.991). When we divided participants by their time of candesartan administration, the relationship between the decrease in log-transformed BNP and asleep SBP was still significant in both the awakening-dosing group (β = 0.21, P = 0.028) and the bedtime-dosing group (β = 0.21, P = 0.029). Furthermore, this relationship was strong in the participants who were receiving diuretics. Conclusion: The decrease in BNP is associated with asleep BP reduction by candesartan (+ diuretics as needed) over and above the awake BP reduction, regardless of the time of administration.

Original languageEnglish
Pages (from-to)1015-1021
Number of pages7
JournalJournal of Hypertension
Volume30
Issue number5
DOIs
Publication statusPublished - May 1 2012

Fingerprint

Brain Natriuretic Peptide
Antihypertensive Agents
Japan
Blood Pressure
Diuretics
Therapeutics
Ambulatory Blood Pressure Monitoring
Multicenter Studies
candesartan

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment : The Japan Morning Surge-Target Organ Protection (J-TOP) study. / Shimizu, Motohiro; Ishikawa, Joji; Yano, Yuichiro; Hoshide, Satoshi; Eguchi, Kazuo; Ishikawa, Shizukiyo; Shimada, Kazuyuki; Kario, Kazuomi.

In: Journal of Hypertension, Vol. 30, No. 5, 01.05.2012, p. 1015-1021.

Research output: Contribution to journalArticle

Shimizu, Motohiro ; Ishikawa, Joji ; Yano, Yuichiro ; Hoshide, Satoshi ; Eguchi, Kazuo ; Ishikawa, Shizukiyo ; Shimada, Kazuyuki ; Kario, Kazuomi. / Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment : The Japan Morning Surge-Target Organ Protection (J-TOP) study. In: Journal of Hypertension. 2012 ; Vol. 30, No. 5. pp. 1015-1021.
@article{796218ec09aa4712bcdbf8889bae3b2c,
title = "Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: The Japan Morning Surge-Target Organ Protection (J-TOP) study",
abstract = "Background: Asleep blood pressure (BP) has been shown to better reflect cardiovascular risk than awake BP in hypertensive patients. This study investigated the correlation of brain natriuretic peptide (BNP) to asleep BP during antihypertensive treatment. Methods: In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which was an open-label multicenter trial to compare bedtime or awakening dosing of candesartan (+ diuretics as needed) among individuals with home SBP higher than 135 mmHg, we evaluated 254 hypertensive patients who underwent ambulatory BP monitoring, and measured their BNP at baseline and after 6th month of treatment. Results: At follow-up, the decrease in log-transformed BNP was significantly related to the decrease in asleep SBP (r = 0.27, P < 0.001); the relationship remained significant (β = 0.20, P = 0.002) even after adjusting for the decrease in the awake SBP (β = 0.001, P = 0.991). When we divided participants by their time of candesartan administration, the relationship between the decrease in log-transformed BNP and asleep SBP was still significant in both the awakening-dosing group (β = 0.21, P = 0.028) and the bedtime-dosing group (β = 0.21, P = 0.029). Furthermore, this relationship was strong in the participants who were receiving diuretics. Conclusion: The decrease in BNP is associated with asleep BP reduction by candesartan (+ diuretics as needed) over and above the awake BP reduction, regardless of the time of administration.",
author = "Motohiro Shimizu and Joji Ishikawa and Yuichiro Yano and Satoshi Hoshide and Kazuo Eguchi and Shizukiyo Ishikawa and Kazuyuki Shimada and Kazuomi Kario",
year = "2012",
month = "5",
day = "1",
doi = "10.1097/HJH.0b013e328351f80b",
language = "English",
volume = "30",
pages = "1015--1021",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment

T2 - The Japan Morning Surge-Target Organ Protection (J-TOP) study

AU - Shimizu, Motohiro

AU - Ishikawa, Joji

AU - Yano, Yuichiro

AU - Hoshide, Satoshi

AU - Eguchi, Kazuo

AU - Ishikawa, Shizukiyo

AU - Shimada, Kazuyuki

AU - Kario, Kazuomi

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Background: Asleep blood pressure (BP) has been shown to better reflect cardiovascular risk than awake BP in hypertensive patients. This study investigated the correlation of brain natriuretic peptide (BNP) to asleep BP during antihypertensive treatment. Methods: In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which was an open-label multicenter trial to compare bedtime or awakening dosing of candesartan (+ diuretics as needed) among individuals with home SBP higher than 135 mmHg, we evaluated 254 hypertensive patients who underwent ambulatory BP monitoring, and measured their BNP at baseline and after 6th month of treatment. Results: At follow-up, the decrease in log-transformed BNP was significantly related to the decrease in asleep SBP (r = 0.27, P < 0.001); the relationship remained significant (β = 0.20, P = 0.002) even after adjusting for the decrease in the awake SBP (β = 0.001, P = 0.991). When we divided participants by their time of candesartan administration, the relationship between the decrease in log-transformed BNP and asleep SBP was still significant in both the awakening-dosing group (β = 0.21, P = 0.028) and the bedtime-dosing group (β = 0.21, P = 0.029). Furthermore, this relationship was strong in the participants who were receiving diuretics. Conclusion: The decrease in BNP is associated with asleep BP reduction by candesartan (+ diuretics as needed) over and above the awake BP reduction, regardless of the time of administration.

AB - Background: Asleep blood pressure (BP) has been shown to better reflect cardiovascular risk than awake BP in hypertensive patients. This study investigated the correlation of brain natriuretic peptide (BNP) to asleep BP during antihypertensive treatment. Methods: In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which was an open-label multicenter trial to compare bedtime or awakening dosing of candesartan (+ diuretics as needed) among individuals with home SBP higher than 135 mmHg, we evaluated 254 hypertensive patients who underwent ambulatory BP monitoring, and measured their BNP at baseline and after 6th month of treatment. Results: At follow-up, the decrease in log-transformed BNP was significantly related to the decrease in asleep SBP (r = 0.27, P < 0.001); the relationship remained significant (β = 0.20, P = 0.002) even after adjusting for the decrease in the awake SBP (β = 0.001, P = 0.991). When we divided participants by their time of candesartan administration, the relationship between the decrease in log-transformed BNP and asleep SBP was still significant in both the awakening-dosing group (β = 0.21, P = 0.028) and the bedtime-dosing group (β = 0.21, P = 0.029). Furthermore, this relationship was strong in the participants who were receiving diuretics. Conclusion: The decrease in BNP is associated with asleep BP reduction by candesartan (+ diuretics as needed) over and above the awake BP reduction, regardless of the time of administration.

UR - http://www.scopus.com/inward/record.url?scp=84859888102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859888102&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e328351f80b

DO - 10.1097/HJH.0b013e328351f80b

M3 - Article

VL - 30

SP - 1015

EP - 1021

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 5

ER -